Form 4: Incyte Executive Michael Morrissey Reports Stock Transaction

Michael Morrissey, EVP at Incyte Corp, reported a transaction involving the withholding of shares to cover tax obligations.

Summary

• Michael Morrissey, an Executive Vice President at Incyte Corp, filed a Form 4 disclosing a transaction.
• The transaction involved the withholding of 908 common stock shares to cover tax obligations.
• The shares were withheld at a price of $72.46 per share.
• Following the transaction, Morrissey beneficially owns 71,392 shares of Incyte common stock, including 23,074 unvested restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine filing of a stock transaction, which is neither positive nor negative.

Industry Context

This is a routine filing related to executive stock transactions and is common for publicly traded companies.

Comparison to Industry Standards

• Form 4 filings are standard practice for corporate insiders in publicly traded companies, such as Incyte, and are required by the SEC.
• The transaction is typical of stock-based compensation where shares are withheld to cover tax obligations, a common practice across the industry.
• Similar filings can be seen from executives at comparable companies such as Gilead Sciences, Vertex Pharmaceuticals, and Regeneron Pharmaceuticals.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine tax withholding event.

Key Dates

Keywords

Form 4, Incyte Corp, Michael Morrissey, Stock Transaction, Beneficial Ownership, Tax Withholding, Restricted Stock Units